Ticker Details
Solid Biosciences Inc. Solid Biosciences Inc is a life science company engaged in developing therapies for Duchenne muscular dystrophy. Its product candidate, SGT-001, is a gene transfer under development to restore functional dystrophin protein expression in patients' muscles.
IPO Date:	January 26, 2018
Sector:	Healthcare
Industry:	Drug Manufacturers
Market Cap:	$997.19M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.35 | 4.37%
Avg Daily Range (30 D):	$0.35 | 3.86%
Avg Daily Range (90 D):	$0.33 | 4.04%

Institutional Daily Volume
Avg Daily Volume:	.82M
Avg Daily Volume (30 D):	.79M
Avg Daily Volume (90 D):	1.16M

Trade Size
Avg Trade Size (Sh.):	148
Avg Trade Size (Sh.) (30 D):	58
Avg Trade Size (Sh.) (90 D):	74

Institutional Trades
Total Institutional Trades:	597
Avg Institutional Trade:	$1.61M
Avg Institutional Trade (30 D):	$1.38M
Avg Institutional Trade (90 D):	$1.98M
Avg Institutional Trade Volume:	.14M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$1.88M
Avg Closing Trade (30 D):	$1.38M
Avg Closing Trade (90 D):	$2.14M
Avg Closing Volume:	186.99K

News

May 26, 2026 @ 5:00 PM Duchenne Muscular Dystrophy Clinical Trial Pipelin... Source: Delveinsight

Dec 16, 2025 @ 9:51 PM Solid Biosciences Announces Duchenne Muscular Dyst... Source: Solid Biosciences Inc.

Dec 1, 2025 @ 1:00 PM Solid Biosciences Receives FDA Rare Pediatric Dise... Source: Solid Biosciences Inc.

Nov 17, 2025 @ 1:00 PM Solid Biosciences Announces Licensing Agreement wi... Source: Solid Biosciences Inc.

Nov 11, 2025 @ 1:00 PM Solid Biosciences to Participate at Upcoming Inves... Source: Nicole Anderson

Financials
	TTM	Q2 2026	Q1 2026
Basic EPS	$-1.89	$-.38	$-.52
Diluted EPS	$-1.91	$-.38	$-.52
Revenue	$M	$M	$M
Gross Profit
Net Income / Loss	$-207.1M	$-54.8M	$-56.74M
Operating Income / Loss	$-212.15M	$-57.38M	$-57.31M
Cost of Revenue
Net Cash Flow	$19.88M	$-137.71M	$236.56M
PE Ratio

Splits
Oct 28, 2022	1:15